Acadia Pharmaceuticals Inc.
Clinical trials sponsored by Acadia Pharmaceuticals Inc., explained in plain language.
-
New hope for Alzheimer's psychosis: drug trial targets hallucinations
Symptom relief Recruiting nowThis study tests an experimental drug called ACP-204 to see if it can reduce hallucinations and delusions in people with Alzheimer's disease psychosis. About 1,074 adults aged 55 to 95 will take either a low dose, high dose, or a placebo pill for 6 weeks. The goal is to find a sa…
Phase: PHASE2, PHASE3 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 17, 2026 01:29 UTC
-
New hope for dementia psychosis: experimental drug enters mid-stage trial
Symptom relief Recruiting nowThis study tests an experimental drug called ACP-204 to see if it can safely reduce psychosis (hallucinations and delusions) in adults with Lewy body dementia. About 180 people aged 55 to 84 will receive either the drug or a placebo for 6 weeks. The goal is to measure changes in …
Phase: PHASE2 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 15, 2026 19:02 UTC
-
New hope for tough depression? drug trial targets Non-Responders
Symptom relief Recruiting nowThis study tests a new medicine called ACP-211 in 153 adults with major depression who didn't get better with at least two antidepressants. The goal is to see if ACP-211 reduces depression symptoms more than a placebo over 28 days. Participants must be 18-65 and currently on a st…
Phase: PHASE2 • Sponsor: ACADIA Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Jun 08, 2026 13:13 UTC